ABBV'S Band of Resistance
ARTICLE SYNOPSIS...AbbVie's (ABBV) stock got slammed after disappointing results on small cell lung cancer drug, Rova-T, test results. The drug was the lead product of Stemcentrix, the biotech company ABBV acquired back in 2016 for $5.8 billion. On Thursday, March 22,
AUTHOR: Stella Osoba, CMTDATE: APR 2018